Addressing a significant need by describing the science and process involved to develop biosimilars of monoclonal antibody (mAb) drugs, this book covers all aspects of biosimilar development: preclinical, clinical, regulatory, manufacturing.
DESCRIPTION
Addressing a significant need by describing the science and process involved to develop biosimilars of monoclonal antibody (mAb) drugs, this book covers all aspects of biosimilar development: preclinical, clinical, regulatory, manufacturing.
• Guides readers through the complex landscape involved with developing biosimilar versions of monoclonal antibody (mAb) drugs
• Features flow charts, tables, and figures that clearly illustrate processes and makes the book comprehensible and accessible
• Includes a review of FDA-approved mAb drugs as a quick reference to facts and useful information
• Examines new technologies and strategies for improving biosimilar mAbs
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